EVT.BRN Stock Chart & Stats
CHF4.63
CHF0.00(0.00%)
―
--
Day’s Range― - ―
52-Week RangeCHF3.85 - CHF27.76
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
CHF564.52M
Enterprise ValueCHF704.44
Total Cash (Recent Filing)CHF444.76M
Total Debt (Recent Filing)CHF387.46M
Price to Earnings (P/E)―
Beta-0.49
Next Earnings
Aug 13, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.09
Shares Outstanding177,909,560
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.20
Price to Book (P/B)1.19
Price to Sales (P/S)1.23
P/FCF Ratio-11.81
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF5.60Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.85
Revenue Forecast (FY)CHF577.89M
Bulls Say, Bears Say
Bulls Say
Diversified Revenue StreamsEvotec's mix of recurring fee-for-service work and downstream partnered R&D economics provides durable revenue optionality. Services deliver steadier cash as pharma outsources discovery, while milestone/royalty upside rewards successful partnerships, supporting medium-term growth even if one stream lags.
Platform Expansion - J.TRAINThe J.TRAIN offering is a structural product expansion: modular cGMP cleanrooms and process automation let partners adopt Evotec's continuous biologics manufacturing. This deepens client relationships, raises switching costs, and can translate into higher-margin, sticky service engagements over the medium term.
Balance Sheet FlexibilityAbsolute leverage appears moderate versus equity, giving Evotec room to fund operations, invest in platform expansion, and weather R&D timing variability. That financial cushion supports strategic execution over months, though it depends on stabilizing cash flows to preserve equity cushion.
Bears Say
Sustained UnprofitabilityEvotec has posted multi-year losses and deeply negative margins, reflecting an earnings structural problem. Persistent unprofitability erodes retained capital, reduces reinvestment ability, and raises reliance on external funding unless margins are restored through efficiency or higher-margin contracts.
Revenue DeclineA declining top line weakens scale economics for a services-heavy business, impeding fixed-cost absorption and margin recovery. Shrinking revenue can also reduce milestone potential and make it harder to sustain investments in platform expansions like modular manufacturing without offsetting new contracts.
Negative Free Cash FlowDespite operating cash improvements, persistent negative free cash flow implies ongoing cash burn after investments. This creates structural funding risk, forcing reliance on financing or asset sales, and constrains long-term investment in R&D infrastructure until FCF sustainably turns positive.
EVT.BRN FAQ
What was Evotec’s price range in the past 12 months?
Evotec lowest stock price was CHF3.85 and its highest was CHF27.76 in the past 12 months.
What is Evotec’s market cap?
Evotec’s market cap is CHF564.52M.
When is Evotec’s upcoming earnings report date?
Evotec’s upcoming earnings report date is Aug 13, 2026 which is in 11 days.
How were Evotec’s earnings last quarter?
Currently, no data Available
Is Evotec overvalued?
According to Wall Street analysts Evotec’s price is currently Undervalued.
Does Evotec pay dividends?
Evotec does not currently pay dividends.
What is Evotec’s EPS estimate?
Evotec’s EPS estimate is -0.07.
How many shares outstanding does Evotec have?
Evotec has 177,909,560 shares outstanding.
What happened to Evotec’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Evotec?
Currently, no hedge funds are holding shares in CH:EVT.BRN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Evotec Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
CHF5.60 (― Downside)
CHF5.60 (― Downside)
Insider Transactions
Sold Shares
Worth CHF592.4K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-37.30%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-15.69%
Trailing 12-Months
Company Description
Evotec
Evotec SE functions as a global collaborator, aiding the pharmaceutical and biotechnology industries in the identification and progression of novel drug candidates. The firm is actively engaged in advancing medicinal products designed to treat a diverse array of health challenges, including diabetes and its related complications, various fibrotic conditions, infectious diseases, disorders of the central nervous system, oncological conditions, pain management, inflammatory and immunological ailments, rare diseases, respiratory illnesses, and women's health concerns. Evotec SE has forged partnerships with a number of significant players in the sector, such as Bayer AG, Lilly, Chinook Therapeutics, Novo Nordisk A/S, Galapagos, Pfizer Inc., CONBA Pharmaceutical Co., Ltd., Bristol Myers Squibb Company, Zhejiang JingXin Pharmaceutical Co., Ltd, Kazia Therapeutics, Apeiron Biologics, and Takeda Pharmaceuticals. The company, initially incorporated as Evotec AG in 1993, underwent a name change to Evotec SE in April 2019 and maintains its corporate headquarters in Hamburg, Germany.
EVT.BRN Stock 12 Month Forecast
Average Price Target
CHF5.60
Biofrontera
―
―
B.R.A.I.N. Biotechnology Research and Information Network
―
Merck KGaA
―
Heidelberg Pharma AG
―